Three related protozoan parasites....three different insect vectors......three very different diseases.....all potentially devastating.
Our Key Objectives
To bring promising anti-trypanosomatid drug discovery initiatives forward with the help of key experts in industry and academia to create a unique and powerful drug discovery platform with the common objective of advancing promising laboratory-driven discoveries into clinical utility. EU FP7 work programme : HEALTH.2013.2.3.4-2: Drug development for neglected parasiticdiseases. FP7-HEALTH-2013-INNOVATION-1. Duration: 36 monthsScientific oordinator Dr. Jane MacDougall PhDjmacdougall@photeomix.com
Drugs against neglected parasitic diseases
The trypanosomatid diseases, Leishmaniasis, Human Africantrypanosomiasis and Chagas disease, continue to impart a heavy toll on human health, affecting millions of people worldwide, particularly those living in the economically poorest countries. The handful of treatments available to control this enormous heath burden is limited by serious adverse effects, high costs, difficulties in administration and the ever advancing spectre of drug resistance. Whilst several drug candidates are under review at the preclinical trials stage, the pipeline remains sparse. There has been general market inertia to translate recent scientific and technological advances into the discovery of potent, safe drug candidates against this devastating group of protozoan parasites. The KINDReD consortium has been drawn together from academia and industry to strengthen and advance the current drug development pipeline. Our ambition is to bring much needed new drug candidates through the preclinical development process with the ultimate aim of gaining regulatory approval for initial phase I clinical trials for each of the three major trypanosomatid diseases.
Kinetoplastid Drug Development strengthening the preclinical pipeline